Lytica Therapeutics

Executive Summary

Lytica Therapeutics is a preclinical-stage biotechnology company headquartered in Boston, developing next-generation antibody-drug conjugates (ADCs) through a proprietary platform designed to enhance ADC internalization and efficacy. Founded in 2022, the company addresses key limitations of conventional ADCs, such as inefficient tumor penetration and drug resistance, by engineering antibodies with optimized cellular uptake properties. Lytica's approach aims to improve the therapeutic index and broaden the application of ADCs across various oncology indications. While still in early development, the company has built a pipeline of proprietary ADC candidates and is seeking collaborations with biotech and pharmaceutical partners to advance its technology.

Upcoming Catalysts (preview)

• Q2 2026Preclinical data presentation at major oncology conference80% success
• Q3 2026Announcement of strategic partnership or licensing deal30% success
• Q4 2026IND-enabling studies completion and potential IND filing for lead candidate25% success